Animals are remarkably efficient in absorbing dietary fat and assimilating this energy-dense nutrient into the white adipose tissue (WAT) for storage. Although this metabolic efficiency may confer an advantage in times of calorie deprivation, it contributes to obesity and associated metabolic disorders when dietary fat is abundant 1,2 . Here we show that the intestinal lipid synthesis enzyme acyl CoA:monoacylglycerol acyltransferase-2 (MGAT2) has a crucial role in the assimilation of dietary fat and the accretion of body fat in mice. Mice lacking MGAT2 have a normal phenotype on a low-fat diet. However, on a high-fat diet, MGAT2-deficient mice are protected against developing obesity, glucose intolerance, hypercholesterolemia and fatty livers. Caloric intake is normal in MGAT2-deficient mice, and dietary fat is absorbed fully. However, entry of dietary fat into the circulation occurs at a reduced rate. This altered kinetics of fat absorption apparently results in more partitioning of dietary fat toward energy dissipation rather than toward storage in the WAT. Thus, our studies identify MGAT2 as a key determinant of energy metabolism in response to dietary fat and suggest that the inhibition of this enzyme may prove to be a useful strategy for treating obesity and other metabolic diseases associated with excessive fat intake.
Animals are remarkably efficient in absorbing dietary fat and assimilating this energy-dense nutrient into the white adipose tissue (WAT) for storage. Although this metabolic efficiency may confer an advantage in times of calorie deprivation, it contributes to obesity and associated metabolic disorders when dietary fat is abundant 1, 2 . Here we show that the intestinal lipid synthesis enzyme acyl CoA:monoacylglycerol acyltransferase-2 (MGAT2) has a crucial role in the assimilation of dietary fat and the accretion of body fat in mice. Mice lacking MGAT2 have a normal phenotype on a low-fat diet. However, on a high-fat diet, MGAT2-deficient mice are protected against developing obesity, glucose intolerance, hypercholesterolemia and fatty livers. Caloric intake is normal in MGAT2-deficient mice, and dietary fat is absorbed fully. However, entry of dietary fat into the circulation occurs at a reduced rate. This altered kinetics of fat absorption apparently results in more partitioning of dietary fat toward energy dissipation rather than toward storage in the WAT. Thus, our studies identify MGAT2 as a key determinant of energy metabolism in response to dietary fat and suggest that the inhibition of this enzyme may prove to be a useful strategy for treating obesity and other metabolic diseases associated with excessive fat intake.
Dietary fat, as triacylglycerol, is a major source of calories, accounting for over 30% of daily intake in most developed countries 3 . The assimilation of triacylglycerol as body fat is remarkably efficient, owing in part to near complete absorption in the small intestine. Intestinal fat absorption involves hydrolysis of dietary triacylglycerol to monoacylglycerol and fatty acids in the lumen, lipid uptake by enterocytes of the proximal small intestine, resynthesis of triacylglycerol and triacylglycerol incorporation into chylomicrons for distribution to tissues. The probable rate-limiting step of triacylglycerol synthesis is formation of diacylglycerol from monoacylglycerol and fatty acyl CoA substrates, catalyzed by MGAT 4, 5 . The MGAT pathway accounts for B75% of triacylglycerol synthesis in the intestine; the remainder is presumably mediated by the glycerol-3-phosphate pathway 6, 7 . Of three identified MGAT enzymes [8] [9] [10] [11] , MGAT2 and MGAT3 are expressed in the small intestine. MGAT2 is highly expressed in the proximal small intestine in both humans and mice, whereas human MGAT3 expression is highest in the distal intestine (the gene is apparently not expressed in mice) [9] [10] [11] . We found mouse Mogat2 mRNA levels were highest in the small intestine; other tissues (for example, kidney, stomach, adipose tissues and liver) had o1% of that in the small intestine 9 ( Supplementary Fig. 1 online) . In the small intestine, Mogat2 mRNA was present in enterocytes of intestinal villi, and levels doubled after high-fat feeding (Supplementary Figs. 1 and 2 online) 12 .
To determine the requirement for MGAT2 in dietary fat absorption, we generated Mogat2 À/À mice, which lack MGAT2 protein and have a greater than 50% decrease in intestinal MGAT activity compared with wild-type mice ( Supplementary Fig. 2 ). Mogat2 À/À mice were born at expected Mendelian frequencies with no apparent abnormalities. On a low-fat chow diet, they gained weight normally, and their body composition was similar to wild-type mice (Fig. 1) . However, on a diet containing 60% calories from fat, male Mogat2 À/À mice gained less than wild-type mice, and Mogat2 +/À mice had an intermediate phenotype (Fig. 1b) . After 16 weeks, Mogat2 À/À mice weighed 40% less than did wild-type mice, and their fat mass was more than 50% lower (Fig. 1b,c) . Lean body mass and body length (data not shown) were similar in mice of both genotypes. Decreased weight gain was also observed in female Mogat2 À/À mice fed the 60% high-fat diet (Fig. 1d) and in male Mogat2 À/À mice fed a diet with 45% calories from fat ( Supplementary Fig. 3 online) . Thus, MGAT2 deficiency protects against obesity caused by a high-fat diet. We did not examine whether MGAT2 deficiency protects against other causes of obesity, such as leptin deficiency, in this study.
Obesity is frequently accompanied by metabolic disorders that can be induced by high-fat diets. We examined whether Mogat2 À/À mice were protected against these conditions. Male Mogat2 À/À mice had lower fasting insulin concentrations and better glucose tolerance after prolonged high-fat feeding (Fig. 2) . They also had lower fasting concentrations of total and non-high-density lipoprotein cholesterol in plasma (Fig. 2b) ; plasma triacylglycerol concentrations were similar in wild-type and Mogat2 À/À mice (37.8 ± 1.9 mg dl À1 versus 32.3 ± 2.7 mg dl À1 , respectively). Mogat2 À/À mice were also protected against hepatic steatosis (Fig. 2c) , with hepatic triacylglycerol content being o5% of that in wild-type mice (6.0 ± 1.6 nmol per mg tissue versus 131 ± 10.5 nmol per mg tissue). Thus, MGAT2 deficiency protects mice from glucose intolerance, hypercholesterolemia and hepatic steatosis induced by a high-fat diet.
To investigate mechanisms underlying the striking phenotype of Mogat2 À/À mice, we examined energy balance. Food intake was similar during 1 week of high-fat feeding, when Mogat2 À/À mice gained less weight than wild-type mice (Fig. 3a) , suggesting differences in energy expenditure. Oxygen consumption during the dark phase of the light cycle, when mice are awake and eating, was B7% higher in Mogat2 À/À mice fed a high-fat diet (Fig. 3b) . Locomotor activity was not increased (Fig. 3c) , suggesting that Mogat2 À/À mice have higher resting metabolic rates, thermogenesis or both. Supporting this notion, their body temperatures on a high-fat diet were higher (Fig. 3d) .
We next examined intestinal absorption of dietary fat. In studies using a nonabsorbable fat 13 as a reference, fat was absorbed at similarly high proportions in Mogat2 À/À and wild-type mice, even when fat accounted for 60% of dietary calories (Fig. 4a) . Fecal fat amounts were similar (6.5 ± 3.1 mg per mouse per day versus 8.4 ± 3.4 mg per mouse per day for wild-type and Mogat2 À/À mice, respectively), as were fecal mass and energy content (Fig. 4b) . Tissue stores of the fat-soluble vitamins A and E were also similar (Fig. 4c) . Chylomicron-sized lipoprotein particles appeared in the circulation of Mogat2 À/À mice after an oral bolus of oil ( Supplementary Fig. 4 online), indicating that Mogat2 is not required for assembly and secretion of chylomicrons. Thus, dietary fat absorption is intact in Mogat2 À/À mice, and normal quantities of fat are absorbed.
The normal dietary fat absorption in Mogat2 À/À mice suggested that they can synthesize triacylglycerol in enterocytes. Indeed, triacylglycerol was the most abundant lipid in the small intestine of Mogat2 À/À mice fed a high-fat diet, and monoacylglycerol, an MGAT2 substrate, did not accumulate in the small intestine (Fig. 4d) . Additionally, acute administration of radioactive monoacylglycerol tracer into the intestinal lumen verified that, within 5 min, triacylglycerol was synthesized in enterocytes of Mogat2 À/À mice in amounts 70% of wild-type levels (data not shown). We suspect intestinal triacylglycerol is synthesized in Mogat2 À/À mice either by another MGAT enzyme 14 , as there was residual activity converting monoacylglycerol to diacylglycerol and triacylglycerol ( Supplementary Fig. 2d ), or by breakdown of monoacylglycerol to glycerol and fatty acid, which enters the glycerol-phosphate pathway. The latter pathway would require more energy than the MGAT pathway and could contribute to the metabolic inefficiency of Mogat2 À/À mice.
Because absorption of dietary fat was quantitatively normal in Mogat2 À/À mice, we hypothesized that their lower propensity for obesity may involve a lower rate of absorption of dietary fat into the circulation. To test this, we examined the rate of triacylglycerol entry 
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Blood glucose (mg dl into the circulation after an intragastric bolus of olive oil. Plasma triacylglycerol concentrations increased transiently in wild-type but not Mogat2 À/À mice ( Supplementary Fig. 4b ). After mice were orally given dietary oil containing 14 C-trioleoylglycerol (administered with tyloxapol, which blocks lipolysis in plasma), the radioactivity and triacylglycerol abundance in plasma accumulated more slowly in Mogat2 À/À mice (Fig. 4e) , confirming a reduced rate of fat entering the circulation. Less fat absorption in the proximal small intestine of Mogat2 À/À mice might result in more fat reaching the distal intestine. Indeed, we observed clusters of lipid droplets in enterocytes of the midintestine (jejunum) of Mogat2 À/À , but not wild-type, mice fed a high-fat diet (Fig. 4f) . Oral dosing of a 14 C-trioleoylglycerol yielded smaller amounts of labeled lipids in the midintestine and larger amounts in the distal intestine of Mogat2 À/À mice compared to wild-type mice (Fig. 4g) . Also, amounts of postprandial glucagon-like peptide-1 (GLP-1), an incretin peptide released by the distal gut in response to nutrients 15 , were larger in Mogat2 À/À mice chronically fed a highfat diet, whereas peptide YY (PYY) levels were similar (Fig. 4h) .
Our data suggest that MGAT2 deficiency diminishes fat uptake in the proximal small intestine and delays fat entry into the circulation, changing the spatiotemporal distribution of fat absorption in the intestine when dietary fat consumption is high. This process may dissociate fat from carbohydrate absorption and insulin secretion and may result in reduced fat storage, enhanced fat oxidation and metabolic inefficiency. How MGAT2 deficiency triggers thermogenesis Cumulative food intake (left) and weight gain (right) of adult male mice (6-7 months old) during a 1-week period after being acclimated to individual housing and a 60% high-fat diet for a week. wild-type, n ¼ 15; Mogat2 À/À , n ¼ 11. (b) Oxygen consumption in wild-type and Mogat2 À/À mice. Male mice (5-6 months old) were acclimated individually in metabolic cages, and experiments were performed for 3 d on 10% fat (chow) or 60% fat (high-fat) diet. Data were normalized by lean body mass and were averages of light or dark phases from 3-day measurements. n ¼ 12 per group. (c) Levels of physical activity in wild-type and Mogat2 À/À mice. Activity was assessed by breaks of light beams, and experiments were performed as described in b. (a) Intestinal fat absorption measured in adult mice fed a diet containing 60% of calories from fat. A nonabsorbable fat was used as a marker 13 . Wild-type, n ¼ 12; Mogat2 À/À , n ¼ 14. (b) Output and energy content determined by an adiabatic bomb calorimeter of feces from mice fed a 60% fat diet. Wild-type n ¼ 9; Mogat2 À/À , n ¼ 8. (c) Total amounts of retinol and retinyl esters (Vit. A) in the liver and the levels of a-tocopherol (Vit. E) in the WAT in 10-month-old male wild-type and Mogat2 À/À mice fed a 60 kcal% fat diet. n ¼ 6 mice per group. (d) Lipids extracted from the intestinal mucosa of mice fed a high-fat diet for 2 d, resolved by thin-layer chromatography using a two-solvent system 22 and stained with iodine vapor. TG, triacylglycerol; DG, diacylglycerol; MG, monoacylglycerol; FA, fatty acid. (e) Plasma triacylglycerol and radioactivity levels in chow-fed female mice after injection of the lipase inhibitor tyloxapol and gavage with olive oil containing 14 C-trioleoylglycerol. Wild-type, n ¼ 7; Mogat2 À/À , n ¼ 6. 
is unclear. We excluded several mechanisms. Increased fat oxidation in the small intestine of Mogat2 À/À mice is unlikely, as mRNA expression of genes involved in fat oxidation showed no differences between genotypes ( Supplementary Fig. 5a online) . In rodents, thermogenesis is often mediated by brown adipose tissue (BAT) and uncoupling protein-1 (UCP-1) 16 . However, Ucp1 mRNA levels were not increased in BAT of Mogat2 À/À mice ( Supplementary Fig. 5b ), and BAT masses were similar (data not shown). BAT of Mogat2 À/À mice fed a high-fat diet was darker and contained fewer lipid droplets than that of wildtype mice, consistent with increased fat oxidation. Also, plasma concentrations of thyroid hormones were normal in Mogat2 À/À mice (data not shown).
We suspect that the delayed fat absorption in Mogat2 À/À mice results in the partitioning of more dietary fat to BAT or other tissues, where it is oxidized. Greater flux would increase uncoupling-mediated thermogenesis in BAT. Ucp2 mRNA levels in BAT were markedly increased ( Supplementary Fig. 5b ), perhaps reflecting greater oxidative stress from increased flux of substrates 17 . Increased flux could also promote uncoupling directly through the ability of fatty acids to promote this process 17 . Delayed fat absorption, with more fat reaching the distal intestine, may also trigger gut-derived neuroendocrine responses that promote fat burning over accretion. Although GLP-1 concentrations were increased in the plasma of Mogat2 À/À mice, this is not a likely mechanism: administering exendin-3(9-39), a GLP-1 receptor antagonist, did not alter body weight (data not shown), and mice lacking the GLP-1 receptor had no changes in body weight 18 .
We identified MGAT2 as a key determinant of energy metabolism in response to dietary fat. These findings may be relevant to human obesity: MGAT2 is expressed in human small intestine 9, 10 , and three microsatellite loci markers encompassing human MOGAT2 on chromosome 11q13.5 are associated with altered resting energy expenditure, whereas one is linked to body-fat percentage 19 . Thus, variations in MOGAT2 expression may contribute to differences in metabolic efficiency and propensity to weight gain in humans consuming diets rich in fat. Our findings also suggest that inhibiting MGAT2 in the small intestine might be useful for treating metabolic diseases caused by excessive fat intake. Attempts to block fat digestion in the intestinal lumen has had limited success in the clinic. Given our findings, the intracellular enzyme MGAT2 seems to be uniquely positioned as a possible intestinal target for interfering with fat absorption.
METHODS
Generation of Mogat2-deficient mice. We generated Mogat2-targeted 129/ SvJae embryonic stem cells and, subsequently, mice carrying this mutation with a targeting vector designed to replace exon 1 of Mogat2, including the translation-initiating methionine, with a neomycin-resistance cassette. We confirmed Mogat2 disruption by Southern blotting of genomic DNA that had been digested with BstXI with a probe hybridizing upstream of sequences included in the targeting vector and by PCR (described in Supplementary  Fig. 2a) . We generated Mogat2 À/À and wild-type littermates from breeding heterozygotes (that were first backcrossed for 10-12 generations with C57BL/6J mice from the Jackson Laboratory) and housed them in a pathogen-free facility. Diets were standard chow, containing 11.9% calories from fat (5053 PicoLab; Purina), or semipurified diets containing 10%, 45% or 60% calories from fat (Research Diets). The University of California-San Francisco Institutional Animal Care and Use Committee approved all procedures involving mice.
Body weight, composition and temperature. To monitor long-term growth, we weaned mice at 3 weeks of age onto the standard chow diet, weighed them weekly between 16:00 and 18:00 and kept them on the low-fat chow or switched them to the 60% high-fat diet at 9 weeks of age. We analyzed body composition by dual-energy X-ray absorptiometry (DEXA) with a PixiMus2 scanner (GE Healthcare Lunar) after a 4-h fast, and we measured body lengths from nose tip to tail base after anesthesia. For monitoring food intake and weight gain in home cages, we acclimatized adult mice to individual caging and to the high-fat diet for a week, weighed them and their food daily and pooled the data for the following 7 d. We measured core body temperature rectally with a digital thermometer (model 4600; Yellow Springs Instruments) between 14:00 and 16:00 after deprivation of food for 4 h (fast) and between 21:00 and 22:00 (ad libitum; fed).
Biochemical assays. We measured plasma triacylglycerol, total cholesterol, HDL-cholesterol, insulin, GLP1 (active), and PYY (total) levels by enzymatic assay or enzyme-linked immunoassay kits (triacylglycerol, Trig/GB, Roche/ Hitachi Diagnostics; cholesterol, Waco Chemicals; insulin, Crystal Chem; GLP1, Millipore; PYY, Diagnostic Systems Laboratories). For GLP1 and PYY, we collected plasma 2 h after feeding and immediately added a dipeptidyl peptidase IV inhibitor (Millipore). We sent samples to Craft Technologies to measure retinol, retinyl esters and a-tocopherol. We measured MGAT activity and tissue triacylglycerol as previously described 8, 20 . We visualized lipids by iodine vapor or by dipping the plate into a solution of 10% cupric sulfate and 8% phosphoric acid and heating to 180 1C. We quantified rriacylglycerol mass was quantified by a previously described method4, with triolein as a standard.
Absorption of dietary fat. We assessed fat absorption during chronic high-fat feeding and after an acute challenge with a bolus of oil. We measured triacylglycerol absorption during high-fat feeding first using the fat balance assay developed by the Mouse Phenotyping Center at the University of Cincinnati 13 . We collected feces from mice fed diets containing the nonabsorbable fat sucrose polybenehate and 60% calories from lard. We calculated fat absorption from the ratios of behenic acid to other fatty acids in diet and feces. We next determined the fat contents of the diet and feces by weight. We monitored food intake and fecal output in individually caged mice fed a highfat (60%) diet over a six-day period. We dried, weighed and ground a portion of diet and collected feces, extracted each with 40 ml of chloroform:methanol (2:1), and weighed lipid residues after the solvents were evaporated. We determined the caloric content of feces with an adiabatic bomb calorimeter (1241 Oxygen Bomb Calorimeter; Parr Instrument Company). For acute studies, we measured plasma triacylglycerol concentrations before (time 0) we had challenged mice with a bolus of 200 ml of olive oil through intragastric gavage and at 1 h, 2 h and 4 h after the challenge. To inhibit the clearance of plasma triacylglycerol, we administered 100 ml of the surfactant tyloxapol (5% in PBS, Sigma) through a tail vein. After 15 min, we collected blood before (time 0) and at 1 h, 2 h and 4 h after we had challenged mice with 200 ml of olive oil containing 2 mCi 14 C-trioleoylglycerol for triacylglycerol measurement and scintillation counting. To visualize chylomicron-size lipoprotein particles, we pooled plasma fractions from 1-h samples, ultracentrifuged them and examined the particles floating on the surface layer (density o 1.006 g ml À1 ) by electron microscopy after negative staining with potassium phosphotungstate 20 .
Distribution of dietary fat uptake. We assessed the uptake of dietary fat along the length of the small intestine by modifying a previously described method 21 . We fasted the mice for 4h and gavaged them with 1 mCi of 14 C-trioleoylglycerol in 100 ml of olive oil. Two hours later, we excised the small intestine (between the base of the stomach and the cecal junction), flushed it with 0.5 mM sodium taurocholate in PBS and cut it into 2-cm segments. We digested each segment with 500 ml of 1 N NaOH at 65 1C for 1 h, mixed it with 5 ml of Hionicfluor liquid scintillation cocktail (PerkinElmer) and measured counts per minute with a scintillation counter.
Energy balance. We measured oxygen consumption and physical activity by a monitoring system (Oxymax; Columbus Instruments) after mice were acclimated to the system and various diets under the regular 12-h light-dark cycle. We took measurements from each cage about every 15 min, and we performed experiments for 3 d per diet condition. We separated the data on the basis of light-dark cycle, pooled and averaged them. We normalized oxygen consumption data to lean body mass, as measured by DEXA scanning on the day before calorimetry studies.
Statistical analyses. We compared means of two groups by the t test for parametric data and the Mann-Whitney rank sum test for nonparametric data. When we compared more than two groups, we performed analysis of variance followed by post hoc tests. For most experiments, we performed two-way analysis of variance to determine whether the effects of genotype and diet were significant; if so, we performed Bonferroni post-tests for group comparisons.
Note: Supplementary information is available on the Nature Medicine website.
